Positive safety and efficacy trends strengthen foralumab's clinical profile for na-SPMS, but the small sample limits statistical significance. Monitor upcoming Phase 2a randomized trial (NCT06292923) for confirmation. The data may provide a near-term catalyst, but risk of placebo-controlled failure remains.
Price Chart
Executive Summary
Tiziana Life Sciences announced updated positive clinical data from its Expanded Access Program for intranasal foralumab in 14 patients with non-active secondary progressive multiple sclerosis (na-SPMS). The data show excellent tolerability, only one disability progression event, and 64% of patients achieving clinically meaningful fatigue improvement (≥4 points on MFIS), though the results are not statistically significant due to the small sample size.
Key Facts
- 14 patients with na-SPMS treated with intranasal foralumab in an Expanded Access Program.
- No new safety signals; treatment well tolerated over extended durations.
- Only 1 disability progression event observed; favorable trend vs. placebo and tolebrutinib arms from HERCULES trial.
- 64% of patients achieved a clinically meaningful ≥4-point improvement on the Modified Fatigue Impact Scale (MFIS).
- Data updated from March 2025 to March 2026; results are trend analysis only, not statistically significant.
Financial Impact
No financial figures provided; the filing is a clinical update with no revenue or earnings impact.
Risk Factors
- Small open-label study with no statistical significance; results may not replicate in larger controlled trials.
- Competing therapies (e.g., tolebrutinib) may set a high bar for efficacy.
- Clinical-stage biotech with no approved products; regulatory and financing risks persist.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001213900-26-058715 |
| Document: ea029148001ex99-1.htm | 0001213900-26-058715 |
| Document: 0001213900-26-058715-index-headers.html | 0001213900-26-058715 |
| Document: 0001213900-26-058715-index.html | 0001213900-26-058715 |
| Document: 0001213900-26-058715.txt | 0001213900-26-058715 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 5d ago | 6-K | $1.01 | awaiting T+20 | — | $0.8907 (−11.81%) |
Oct 16, 2026 9d ago | 6-K | $1.01 | awaiting T+20 | — | $0.8907 (+11.81%) |
Oct 16, 2026 10d ago | 6-K | $1.05 | awaiting T+20 | — | $0.8907 (−15.17%) |
Sep 30, 2026 26d ago | 6-K | $1.11 | awaiting T+20 | — | $0.8907 (−19.76%) |
Sep 28, 2026 28d ago | 6-K | $0.9800 | awaiting T+20 | — | $0.8907 (−9.11%) |
Sep 21, 2026 5w ago | 6-K | $0.9046 $1.01 | ▲ +11.65% | ▲ +12.56% | $0.8907 (−1.54%) |
Sep 17, 2026 5w ago | 6-K | $0.9700 $1.05 | ▲ +8.25% | ▲ +7.04% | $0.8907 (−8.18%) |
Sep 17, 2026 5w ago | Press Release | $0.9700 $1.05 | ▲ +8.25% | ▲ +7.04% | $0.8907 (−8.18%) |
Aug 24, 2026 9w ago | 6-K | $1.15 $0.8899 | ▼ −22.62% | ▼ −23.93% | $0.8907 (−22.55%) |
Aug 6, 2026 11w ago | 6-K | $0.9700 $0.9745 | ▲ +0.46% | ▼ −0.14% | $0.8907 (−8.18%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers